IHC staining showed that the expression of BARD1 and BRCA1 was significantly increased in the recurrent tamoxifen-resistant tumors than that in primary tumors (Fig. 6a, b), in agreement with the finding of upregulated BARD1 and BRCA1 in tamoxifen-resistant breast cancer cell lines. This evidence concerns the gene BARD1 and breast cancer.